secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001437749-23-012904
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra CEO Richard Pascoe resigns effective June 1, 2023; two directors not standing for re-election
--------------------------------------------------------------------------------

- CEO Richard Pascoe resigned effective June 1, 2023; transition agreement provides 12 months base salary, pro-rated bonus, extended option exercise period.
- Directors Matthew Plooster and Joseph Saluri will not stand for re-election at 2024 annual meeting; will resign once board finds replacements.
- Board to immediately search for director candidates to fill the pending vacancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/0001437749-23-012904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/zvra20230507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-012904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer